---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016287"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:52:24.805343+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Dare Bioscience Q1 cash $19.8M; Sildenafil Cream Phase 2b data and XACIATO launch expected Q2

## Summary
- Cash $19.8M at March 31; G&A $3.3M (up from $2.6M) on commercial-readiness and email fraud loss; R&D $5.0M (down from $5.8M).
- Expects Sildenafil Cream Phase 2b topline data in Q2 2023 for FSAD, a condition with no FDA-approved treatments.
- XACIATO first commercial sale by Organon expected Q2 2023, triggering $2.5M milestone payment to Daré.
- Ovaprene pivotal Phase 3 contraceptive study start mid-2023 under NIH/NICHD CRADA; DARE-HRT1 and DARE-VVA1 IND prep ongoing.

## SEC filing metadata
- accession: 0001493152-23-016287
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315223016287/0001493152-23-016287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315223016287/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016287
- JSON: https://secwatch.observer/filing/0001493152-23-016287.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016287.txt

## Key facts
- Earnings Releases
  Dare Bioscience, Inc. reported financial results for first fiscal quarter ended March 31, 2023.
  - Period: first fiscal quarter ended March 31, 2023
  - Result: reported results
  source text: Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended March 31, 2023 and provided a company update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315223016287/0001493152-23-016287-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.